General Information of Drug (ID: DMZDN4W)

Drug Name
L-alanine Drug Info
Synonyms
ALA; Alaninum; LPG; Polyalanine; A-Alanine; A-Aminopropionic acid; Alanina [DCIT,Spanish]; Alanine (USP); L-A-Aminopropionicacid; L-Alanine (9CI); L-Alanine (JAN); L-Alanine, homopolymer; L-Alanine, labeled with tritium; L-a-Alanine; L-a-Aminopropionic acid; Poly-DL-alanine; L-Alanine, labeled with carbon-14; Alanine, L-(7CI,8CI); F4F207FF-8FF8-4789-99A1-147AE0A36673; L-Alanine, N-coco alkyl derivs.; Propanoic acid, 2-amino-, (S); (C14)L-Alanine; (S)-2-Aminopropionic acid; 14C-L-Alanine
Indication
Disease Entry ICD 11 Status REF
Dietary shortage 5B5K Approved [1] , [2] , [3]
Glioma 2A00.0 Approved [1] , [2] , [3]
Therapeutic Class
Dietary supplement
Cross-matching ID
PubChem CID
5950
ChEBI ID
CHEBI:16977
CAS Number
CAS 56-41-7
TTD Drug ID
DMZDN4W
VARIDT Drug ID
DR00142

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
D-Serine DM3YH4I N. A. N. A. Phase 4 [7]
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-glutamine DM69G8X Short bowel syndrome KB89.1 Approved [5]
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-glutamine DM69G8X Short bowel syndrome KB89.1 Approved [5]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [8]
L-glutamine DM69G8X Short bowel syndrome KB89.1 Approved [5]
Aminosalicylic acid DMENSL5 Inflammatory bowel disease DD72 Approved [9]
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-glutamine DM69G8X Short bowel syndrome KB89.1 Approved [5]
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-glutamine DM69G8X Short bowel syndrome KB89.1 Approved [5]
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-tryptophan DMIBH7M Depression 6A70-6A7Z Approved [6]
Glycine DMIOZ29 Malnutrition 5B50-5B71 Approved [6]
L-Proline DMKSTWR Malnutrition 5B50-5B71 Approved [6]
L-Phenylalanine DMQXI9F Malnutrition 5B50-5B71 Approved [10]
L-tyrosine DM9O8DT Malnutrition 5B50-5B71 Approved [6]
Drug(s) Targeting GABA transaminase (ABAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyridoxal Phosphate DMO2K0J Malnutrition 5B50-5B71 Approved [4]
Pyruvic acid DM7Q41G Malnutrition 5B50-5B71 Approved [4]
Vigabatrin DMYT0OG Complex partial seizure 8A68.0 Approved [11]
Divalproex sodium DM4RK0G Seizure disorder 8A6Z Approved [4]
CPP-115 DMK9NQI Tourette syndrome 8A05.00 Phase 2 [12]
K-828-AB DMJLNZQ Dementia 6D80-6D86 Phase 2 [13]
CPP -15 DMQCHU3 Infantile spasm 8A62.0 Phase 1 [12]
T83193 DMHO29Y Discovery agent N.A. Patented [14]
4-hydroxybenzaldehyde DM471P5 Discovery agent N.A. Patented [15]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA transaminase (ABAT) TTT2LD9 GABT_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Sodium-coupled neutral amino acid transporter 3 (SLC38A3) DTKWJH3 S38A3_HUMAN Substrate [5]
Sodium-coupled neutral amino acid transporter 5 (SLC38A5) DTLX28N S38A5_HUMAN Substrate [5]
Sodium-coupled neutral amino acid transporter 4 (SLC38A4) DTPJBD5 S38A4_HUMAN Substrate [5]
Sodium-coupled neutral amino acid transporter 2 (SLC38A2) DTTWL58 S38A2_HUMAN Substrate [5]
Sodium-coupled neutral amino acid transporter 1 (SLC38A1) DTD815L S38A1_HUMAN Substrate [5]
L-type amino acid transporter 2 (SLC7A8) DTJF3DX LAT2_HUMAN Substrate [6]
Alanine/serine/cysteine/threonine transporter 1 (SLC1A4) DTC54PX SATT_HUMAN Substrate [7]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 720).
2 Drug information of L-Alanine, Health Canada, 2008. (drugid: 7638)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
5 Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11.
6 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.3.8.20)
7 D-Serine Is a Substrate for Neutral Amino Acid Transporters ASCT1/SLC1A4 and ASCT2/SLC1A5, and Is Transported by Both Subtypes in Rat Hippocampal Astrocyte Cultures. PLoS One. 2016 Jun 7;11(6):e0156551.
8 Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism. Biochem Pharmacol. 1995 Jun 16;49(12):1759-67.
9 Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000 May 15;348 Pt 1:159-66.
10 Quantifying the relative contributions of different solute carriers to aggregate substrate transport. Sci Rep. 2017 Jan 16;7:40628.
11 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
12 Clinical pipeline report, company report or official report of Catalyst Pharma.
13 Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd.
14 Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5.
15 Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4.
16 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.